株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

味の素製薬 - 製品パイプライン分析

Ajinomoto Pharmaceuticals Co., Ltd. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 256129
出版日 ページ情報 英文 36 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
味の素製薬 - 製品パイプライン分析 Ajinomoto Pharmaceuticals Co., Ltd. - Product Pipeline Review - 2015
出版日: 2015年04月15日 ページ情報: 英文 36 Pages
概要

味の素製薬は、医薬品と病人食を開発・製造している製薬会社です。同社は、バイオ及びアミノ酸技術の研究開発力を活かして食品、アミノ酸、医療・ヘルスケア部門で製品を供給しています。

当レポートでは、味の素製薬における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

味の素製薬の基本情報

味の素製薬の概要

  • 主要情報
  • 企業情報

味の素製薬:R&Dの概要

  • 主な治療範囲

味の素製薬:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

味の素製薬:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

味の素製薬:薬剤プロファイル

  • AJM-300
  • budesonide
  • APY-0201
  • Small Molecule to Inhibit NF-kappaB for Inflammation
  • Small Molecules to Inhibit Protein-Protein Interaction for Undisclosed Indication

味の素製薬:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

味の素製薬:最近のパイプライン動向

味の素製薬:休止中のプロジェクト

味の素製薬:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • mesalamine

味の素製薬:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC06930CDB

Summary

Global Markets Direct's, 'Ajinomoto Pharmaceuticals Co., Ltd. - Product Pipeline Review - 2015', provides an overview of the Ajinomoto Pharmaceuticals Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Ajinomoto Pharmaceuticals Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Ajinomoto Pharmaceuticals Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Ajinomoto Pharmaceuticals Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Ajinomoto Pharmaceuticals Co., Ltd.'s pipeline products

Reasons to buy

  • Evaluate Ajinomoto Pharmaceuticals Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Ajinomoto Pharmaceuticals Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Ajinomoto Pharmaceuticals Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Ajinomoto Pharmaceuticals Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ajinomoto Pharmaceuticals Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Ajinomoto Pharmaceuticals Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Ajinomoto Pharmaceuticals Co., Ltd. Snapshot
    • Ajinomoto Pharmaceuticals Co., Ltd. Overview
    • Key Information
    • Key Facts
  • Ajinomoto Pharmaceuticals Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Ajinomoto Pharmaceuticals Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Ajinomoto Pharmaceuticals Co., Ltd. - Pipeline Products Glance
    • Ajinomoto Pharmaceuticals Co., Ltd. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Ajinomoto Pharmaceuticals Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Ajinomoto Pharmaceuticals Co., Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Ajinomoto Pharmaceuticals Co., Ltd. - Drug Profiles
    • AJM-300
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • budesonide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • elobixibat
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • APY-0201
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize Notch-1 for Oncology and Hematological Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit IL-6 for Autoimmune Disorders and Allergies
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit NF-kappaB for Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Ajinomoto Pharmaceuticals Co., Ltd. - Pipeline Analysis
    • Ajinomoto Pharmaceuticals Co., Ltd. - Pipeline Products by Target
    • Ajinomoto Pharmaceuticals Co., Ltd. - Pipeline Products by Route of Administration
    • Ajinomoto Pharmaceuticals Co., Ltd. - Pipeline Products by Molecule Type
    • Ajinomoto Pharmaceuticals Co., Ltd. - Pipeline Products by Mechanism of Action
  • Ajinomoto Pharmaceuticals Co., Ltd. - Recent Pipeline Updates
  • Ajinomoto Pharmaceuticals Co., Ltd. - Dormant Projects
  • Ajinomoto Pharmaceuticals Co., Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • mesalamine
  • Ajinomoto Pharmaceuticals Co., Ltd. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Ajinomoto Pharmaceuticals Co., Ltd., Key Information
  • Ajinomoto Pharmaceuticals Co., Ltd., Key Facts
  • Ajinomoto Pharmaceuticals Co., Ltd. - Pipeline by Indication, 2015
  • Ajinomoto Pharmaceuticals Co., Ltd. - Pipeline by Stage of Development, 2015
  • Ajinomoto Pharmaceuticals Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Ajinomoto Pharmaceuticals Co., Ltd. - Partnered Products in Pipeline, 2015
  • Ajinomoto Pharmaceuticals Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2015
  • Ajinomoto Pharmaceuticals Co., Ltd. - Phase III, 2015
  • Ajinomoto Pharmaceuticals Co., Ltd. - Phase II, 2015
  • Ajinomoto Pharmaceuticals Co., Ltd. - Preclinical, 2015
  • Ajinomoto Pharmaceuticals Co., Ltd. - Pipeline by Target, 2015
  • Ajinomoto Pharmaceuticals Co., Ltd. - Pipeline by Route of Administration, 2015
  • Ajinomoto Pharmaceuticals Co., Ltd. - Pipeline by Molecule Type, 2015
  • Ajinomoto Pharmaceuticals Co., Ltd. - Pipeline Products by Mechanism of Action, 2015
  • Ajinomoto Pharmaceuticals Co., Ltd. - Recent Pipeline Updates, 2015
  • Ajinomoto Pharmaceuticals Co., Ltd. - Dormant Developmental Projects,2015
  • Ajinomoto Pharmaceuticals Co., Ltd. - Discontinued Pipeline Products, 2015

List of Figures

  • Ajinomoto Pharmaceuticals Co., Ltd. - Pipeline by Top 10 Indication, 2015
  • Ajinomoto Pharmaceuticals Co., Ltd. - Pipeline by Stage of Development, 2015
  • Ajinomoto Pharmaceuticals Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Ajinomoto Pharmaceuticals Co., Ltd. - Partnered Products in Pipeline, 2015
  • Ajinomoto Pharmaceuticals Co., Ltd. - Pipeline by Top 10 Target, 2015
  • Ajinomoto Pharmaceuticals Co., Ltd. - Pipeline by Top 10 Route of Administration, 2015
  • Ajinomoto Pharmaceuticals Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015
  • Ajinomoto Pharmaceuticals Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top